REFERENCES
1. Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine 2019;39:612-20.
3. Martínez-martín S, Soucek L. MYC inhibitors in multiple myeloma. Cancer Drug Resist 2021;4:842-65.
4. Uckun FM. Overcoming the Immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel) 2021;13:2018.
5. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136:936-45.
6. Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol 2020;38:775-83.
7. Fayon M, Martinez-Cingolani C, Abecassis A, et al. Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica 2021;106:1193-7.
8. Alhallak K, Sun J, Jeske A, et al. Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges. Cancers (Basel) 2021;13:2853.
9. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314-24.
10. Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398:665-74.
11. Berdeja JG, Krishnan AY, Oriol A, et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). J Clin Oncol 2021;39:8008.
12. Gozzetti A, Ciofini S, Sicuranza A, et al. Drug resistance and minimal residual disease in multiple myeloma. Cancer Drug Resist 2022;5:171-83.
13. Moscvin M, Ho M, Bianchi G. Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resist 2021;4:1028-46.
14. Black H, Glavey S. Gene expression profiling as a prognostic tool in multiple myeloma. Cancer Drug Resist 2021;4:1008-18.
15. Giannoni P, de Totero D. The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma. Cancer Drug Resist 2021;4:923-33.
16. Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel) 2020;12:407.
17. Mynott RL, Wallington-Beddoe CT. Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma. ACS Pharmacol Transl Sci 2021;4:1050-65.
18. Mynott RL, Wallington-Beddoe CT. Inhibition of P-glycoprotein does not increase the efficacy of proteasome inhibitors in multiple myeloma cells. ACS Pharmacol Transl Sci 2021;4:713-29.
19. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 2019;33:2266-75.
20. Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol 2021;22:e105-18.
21. Davis LN, Sherbenou DW. Emerging therapeutic strategies to overcome drug resistance in multiple myeloma. Cancers (Basel) 2021;13:1686.
22. Haertle L, Barrio S, Munawar U, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood 2021;138:1721-6.
23. Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, Pitson SM. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br J Haematol 2018;182:11-28.
24. Barrio S, Stühmer T, Da-Viá M, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2019;33:447-56.
25. Puła A, Robak P, Robak T. MicroRNA in multiple myeloma - a role in pathogenesis and prognostic significance. Curr Med Chem 2021;28:6753-72.
26. Muz B, Kusdono HD, King J, et al. Targeting CD47 As a novel therapeutic strategy in multiple myeloma. Blood 2017;130:3099.
27. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012;26:2538-45.
28. Rastgoo N, Wu J, Liu A, et al. Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica 2020;105:2813-23.
29. Chen H, Cao W, Chen J, et al. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28. J Cell Biochem 2021;122:305-14.
30. Wang Q, Zhao D, Xian M, et al. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood 2020;136:2557-73.
31. Bajpai R, Matulis SM, Wei C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 2016;35:3955-64.
32. Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013;12:329-41.
33. Jones CL, Stevens BM, D’Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 2018;34:724-40.e4.
34. Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130:2401-9.
35. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2020;21:1630-42.
36. Bolomsky A, Miettinen JJ, Malyutina A, et al. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021;5:4125-39.
37. Cohen YC, Zada M, Wang SY, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 2021;27:491-503.
38. Goicoechea I, Puig N, Cedena MT, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood 2021;137:49-60.
39. Sherbenou DW, Su Y, Behrens CR, et al. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. Clin Cancer Res 2020;26:6028-38.
40. Uckun FM. Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma. Front Oncol 2021;11:760382.
41. Fontana F, Scott MJ, Allen JS, et al. VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival. Clin Cancer Res 2021;27:1974-86.
42. Byrgazov K, Kraus M, Besse A, et al. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res 2021;101:106499.
43. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727-38.
44. Innao V, Rizzo V, Allegra AG, Musolino C, Allegra A. Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma. Cells 2021;10:439.
